BACKGROUND: Thymic malignancies are rare tumors. The insulin-like growth factor-1 (IGF-1)/IGF-1 receptor (IGF-1R) system is involved in the development of the thymus. IGF-1R expression in thymic epithelial malignancies is unknown. METHODS: The authors investigated the expression of IGF-1R and phosphorylated AKT serine 473 (p-AKT) by using immunohistochemistry and examined the clinicopathologic correlations in a retrospective, single-institution surgical series of 132 patients with thymic epithelial malignancies. RESULTS: Earlier disease stage, less aggressive histologic types, and complete resection were significant positive prognostic factors for disease-related survival and progression-free survival, and being a woman was a better prognostic factor for disease-related survival. IGF-1R and p-AKT protein levels were expressed in 20% and 36% of thymic tumors, respectively. Both markers were expressed more commonly in recurrent disease than in primary tumors, in more aggressive subtypes, and in more advanced disease stages. There was a trend toward better survival and progression-free survival in patients who were negative for IGF-1R or p-AKT expression in the whole series. When only the 91 primary tumors, IGF1R expression was associated with worse progression-free survival (P < .001). CONCLUSIONS: The current retrospective analysis demonstrated that disease stage, tumor histology, sex, and resection type were major prognostic factors in the survival of patients with thymic malignancies. The expression levels of IGF-1R and p-AKT in thymic tumors suggested that IGF-1R is a potential target for treatment.
BACKGROUND:Thymic malignancies are rare tumors. The insulin-like growth factor-1 (IGF-1)/IGF-1 receptor (IGF-1R) system is involved in the development of the thymus. IGF-1R expression in thymic epithelial malignancies is unknown. METHODS: The authors investigated the expression of IGF-1R and phosphorylated AKTserine 473 (p-AKT) by using immunohistochemistry and examined the clinicopathologic correlations in a retrospective, single-institution surgical series of 132 patients with thymic epithelial malignancies. RESULTS: Earlier disease stage, less aggressive histologic types, and complete resection were significant positive prognostic factors for disease-related survival and progression-free survival, and being a woman was a better prognostic factor for disease-related survival. IGF-1R and p-AKT protein levels were expressed in 20% and 36% of thymic tumors, respectively. Both markers were expressed more commonly in recurrent disease than in primary tumors, in more aggressive subtypes, and in more advanced disease stages. There was a trend toward better survival and progression-free survival in patients who were negative for IGF-1R or p-AKT expression in the whole series. When only the 91 primary tumors, IGF1R expression was associated with worse progression-free survival (P < .001). CONCLUSIONS: The current retrospective analysis demonstrated that disease stage, tumor histology, sex, and resection type were major prognostic factors in the survival of patients with thymic malignancies. The expression levels of IGF-1R and p-AKT in thymic tumors suggested that IGF-1R is a potential target for treatment.
Authors: Masayoshi Inoue; Petr Starostik; Andreas Zettl; Philipp Ströbel; Stephan Schwarz; Francesco Scaravilli; Kristin Henry; Nick Willcox; Hans-Konrad Müller-Hermelink; Alexander Marx Journal: Cancer Res Date: 2003-07-01 Impact factor: 12.701
Authors: Gang Chen; Alexander Marx; Wen-Hu Chen; Jiang Yong; Bernhard Puppe; Philipp Stroebel; Hans Konrad Mueller-Hermelink Journal: Cancer Date: 2002-07-15 Impact factor: 6.860
Authors: Petrini Petrini; Christopher A French; Arun Rajan; Michael J Cameron; Elaine S Jaffe; Paolo A Zucali; Jianwu Xie; Yisong Wang; Giuseppe Giaccone Journal: J Thorac Oncol Date: 2012-04 Impact factor: 15.609
Authors: Arun Rajan; Corey A Carter; Arlene Berman; Liang Cao; Ronan J Kelly; Anish Thomas; Sean Khozin; Ariel Lopez Chavez; Isabella Bergagnini; Barbara Scepura; Eva Szabo; Min-Jung Lee; Jane B Trepel; Sarah K Browne; Lindsey B Rosen; Yunkai Yu; Seth M Steinberg; Helen X Chen; Gregory J Riely; Giuseppe Giaccone Journal: Lancet Oncol Date: 2014-01-15 Impact factor: 41.316
Authors: Fabio Conforti; Xu Zhang; Guanhua Rao; Tommaso De Pas; Yoko Yonemori; Jose Antonio Rodriguez; Justine N McCutcheon; Raneen Rahhal; Anna T Alberobello; Yisong Wang; Yu-Wen Zhang; Udayan Guha; Giuseppe Giaccone Journal: Cancer Res Date: 2017-08-17 Impact factor: 12.701
Authors: P A Zucali; L Di Tommaso; I Petrini; S Battista; H S Lee; M Merino; E Lorenzi; E Voulaz; F De Vincenzo; M Simonelli; M Roncalli; L Giordano; M Alloisio; A Santoro; G Giaccone Journal: Lung Cancer Date: 2012-12-29 Impact factor: 5.705
Authors: Giovannella Palmieri; Carlo Buonerba; Piera Federico; Luigi Formisano; Lucia Nappi; Giuseppe Di Lorenzo; Mirella Marino; Vincenzo Damiano Journal: World J Clin Oncol Date: 2012-07-10
Authors: Iacopo Petrini; Yisong Wang; Paolo A Zucali; Hye Seung Lee; Trung Pham; Donna Voeller; Paul S Meltzer; Giuseppe Giaccone Journal: Clin Cancer Res Date: 2013-02-26 Impact factor: 12.531
Authors: Iacopo Petrini; Paul S Meltzer; In-Kyu Kim; Marco Lucchi; Kang-Seo Park; Gabriella Fontanini; James Gao; Paolo A Zucali; Fiorella Calabrese; Adolfo Favaretto; Federico Rea; Jaime Rodriguez-Canales; Robert L Walker; Marbin Pineda; Yuelin J Zhu; Christopher Lau; Keith J Killian; Sven Bilke; Donna Voeller; Sivanesan Dakshanamurthy; Yisong Wang; Giuseppe Giaccone Journal: Nat Genet Date: 2014-06-29 Impact factor: 38.330